TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02224456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with GILEAD and 4331 on one side of the tablet.
Study: NCT04409665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
Study: NCT03389386

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood withdrawal for laboratory analysis
Description: Participants in this study will have their peripheral blood sampled from the cubital vein and the total volume withdrawn for the purposes of this study will be no more than 22 mL per person.~Parameters of interest in the laboratory analysis will include serum catestatin levels, NT-proBNP levels, hs-cTnI, parameters of inflammation and renal function as well as standard biochemistry and complete blood count (CBC) panels.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood withdrawal for laboratory analysis
Description: Participants in this study will have their peripheral blood sampled from the cubital vein and the total volume withdrawn for the purposes of this study will be no more than 22 mL per person.~Parameters of interest in the laboratory analysis will include serum catestatin levels, NT-proBNP levels, hs-cTnI, parameters of inflammation and renal function as well as standard biochemistry and complete blood count (CBC) panels.

Intervention type: OTHER
Intervention: Standard-of-care treatment
Description: Patients diagnosed with chronic heart failure will receive optimal standards of care in terms of pharmacologic management, according to their current clinical condition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography (TTE)
Description: Participants from both groups will undergo transthoracic echocardiography examination that will measure established hemodynamic parameters of systolic and diastolic cardiac function as well as parameters of LV and RV strain in the selected subset of patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography (TTE)
Description: Participants from both groups will undergo transthoracic echocardiography examination that will measure established hemodynamic parameters of systolic and diastolic cardiac function as well as parameters of LV and RV strain in the selected subset of patients.
Study: NCT04574583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 will be given orally at designated dose twice a day every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 will be given orally at designated dose twice a day every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 will be given orally at designated dose twice a day every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-CV301
Description: MVA-BN-CV301 will be given as four subcutaneous injections (4x10\^8 Inf.U/0.5ml twice during Cycle 1 (Days 1 and 15)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-CV301
Description: MVA-BN-CV301 will be given as four subcutaneous injections (4x10\^8 Inf.U/0.5ml twice during Cycle 1 (Days 1 and 15)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-CV301
Description: MVA-BN-CV301 will be given as four subcutaneous injections (4x10\^8 Inf.U/0.5ml twice during Cycle 1 (Days 1 and 15)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox viral (FPV)-CV301
Description: FPV-CV301 will be given as one subcutaneous injection (1x10\^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles 8 and Cycle 11).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox viral (FPV)-CV301
Description: FPV-CV301 will be given as one subcutaneous injection (1x10\^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles 8 and Cycle 11).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox viral (FPV)-CV301
Description: FPV-CV301 will be given as one subcutaneous injection (1x10\^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles 8 and Cycle 11).
Study: NCT03526965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Chikitsa
Description: Intervention consisted of combination of static movements, yoga style exercise, yoga postures, breathing practices, relaxation and yoga counselling.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Intervention included pain medications and exercise movements for neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Intervention included pain medications and exercise movements for neck.
Study: NCT02201251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate weight based dosing for participants 2 to \<10 years of age not to exceed 350 mg/day, as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
Study: NCT01197963

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sleeve Gastrectomy and Ileal transposition
Description: Laparoscopic sleeve gastrectomy with ileal transposition

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: dietary and medical management
Description: dietary and medical routine management patients are currently following with an endocrinologist.
Study: NCT03301909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam™ Endoscopy System
Description: Subject may be assigned to any procedure involving modification of any of the PillCam™ Endoscopy System component as listed in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowel prep combination
Description: Subject may be assigned to any bowel preparation combination.
Study: NCT03630666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IADT
Description: Patient will receive one injection of IADT at randomization

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IADT + radiotherapy
Description: Patient will receive one injection of IADT at randomization then will receive irradiation 3 months after injection of IADT
Study: NCT03202758

Intervention type: DRUG
Group type: OTHER
Intervention: Durvalumab, Tremelimumab and ,FOLFOX
Description: Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX
Study: NCT04094870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: daily SSRI (Sertraline 25mg)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal therapy
Description: 11 sessions over a 24-week period
Study: NCT01769209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered subcutaneously (SC) at 1.3 mg/m², on Days 1, 4, 8, and 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride (HCl)
Description: Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Asparaginase
Description: Administered intravenously (IV) or intramuscularly (IM) 2500 U/m² (maximum 3750 U), on Days 5 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate
Description: Administered by intravenous (IV) push at 1.5 mg/m² (maximum 2 mg), on Days 1, 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally (PO) at 10 mg/m², daily on Days 1 to 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Administered intrathecally (IT) at 100 mg, on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered intrathecally (IT) at 15 mg, on Day 15.
Study: NCT01220349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiographic 2D strain analysis
Description: Conventional transthoracic echocardiography with acquisitions for strain analysis by speckle tracking (2D strain)
Study: NCT01489722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1208
Description: Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
Study: NCT02637193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Multiple doses of Venlafaxine for 14 days plus 3 days of down titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg single dose moxifloxacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug - placebo
Description: Placebo administered for 16 days
Study: NCT02322047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Naltrexone Dosing Days 1-42: 50mg @ 9PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone Dosing Days 1-42: 50mg @ 9PM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Prazosin)
Description: Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Prazosin)
Description: Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Naltrexone)
Description: Placebo Dosing Days 1-42: 50mg @ 9PM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Naltrexone)
Description: Placebo Dosing Days 1-42: 50mg @ 9PM
Study: NCT01572766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FRAX Assessment Tool
Description: FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
Study: NCT01876862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment interruption
Description: pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
Study: NCT02282319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal dexmedetomidine 0.5 mcg
Description: Administration of dexmedetomidine 0.5 mcg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal chloroprocaine 40 mg
Description: spinal anesthesia with chloroprocaine 40 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal chloroprocaine 40 mg
Description: spinal anesthesia with chloroprocaine 40 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal chloroprocaine 40 mg
Description: spinal anesthesia with chloroprocaine 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine 0.5 mcg/kg
Description: intravenous administration of dexmedetomidine 0.5 mcg/kg
Study: NCT02551744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: histamine-2 receptor antagonist group
Description: famotidine tab 40 mg qd for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: proton pump inhibitor group
Description: pantoprazole tab 40 mg qd for 6 months.
Study: NCT02058420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low tocotrienols group
Description: 300 mg tocotrienols daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High tocotrienols group
Description: 600 mg tocotrienols daily
Study: NCT02479035

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red raspberry meal 1
Description: \~125 g fresh weight (1 cup equivalent)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red raspberry meal 2
Description: \~250 g fresh weight (2 cup equivalent)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control meal
Description: 0 g red raspberry
Study: NCT04132570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\\- 3 Days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\\- 3 Days.
Study: NCT01359618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single dose, oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single dose, oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single dose, oral tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Single dose, oral tablets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo comparator
Description: Single dose, oral tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Single dose, oral tablets
Study: NCT04584879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard UP Treatment
Description: Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard UP Treatment
Description: Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capitalization UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capitalization UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensation UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensation UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
Study: NCT02470299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds~Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose
Study: NCT02316392

Intervention type: DRUG
Intervention: Hyperpolarized Helium-3 MRI
Description: Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
Study: NCT01919177

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate rich beetroot juice
Description: Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate depleted beetroot juice
Description: Subjects will receive 140 mL of nitrate-depleted beetroot juice.
Study: NCT03821064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of clinic-based sessions of manualized PN to reduce barriers to care, increase HNC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months). The three in-person NDURE sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit. During the first session, the navigator will 1) elicit barriers and facilitators to timely PORT, 2) develop the personalized barrier reduction plan (BRP), review the BRP with the patient, caregiver, and provider, and 3) implement the BRP. At the two subsequent sessions, the navigator will review and update the BRP in an iterative, dynamic fashion, identifying new barriers and systematically tracking resolution of prior barriers until the start of PORT.
Study: NCT03494985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Oralbalance Moisturizing Gel
Description: Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene Original Oral Rinse
Description: Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene Moisturizing Mouth Spray
Description: Participants sprayed one jet directly into their mouth. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water
Description: Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use. After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required.
Study: NCT02480751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06297031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: heat application
Description: • Thermophore Application: Before the application, the thermophore was wrapped in a towel to prevent skin damage. Studies in the literature indicate that the surface temperature of the thermophore should be 38-45 °C. For this reason, water with a temperature of 70°C when measured with a thermometer was added into the thermophore. Similarly, studies in the literature indicate that thermophore application should be applied for 10-30 minutes. Therefore, the application takes 20 minutes. The researcher stayed with the woman for 20 minutes.
Study: NCT04359264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: Cash transfer of $1000
Study: NCT03383575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies